“South Africa has become the continent’s leader in rolling out lenacapavir (LEN), the world’s newest HIV prevention injection, with more than 31,000 users in just six weeks. Uptake has been overwhelmingly positive, with nearly all eligible individuals choosing the injection over daily pills, signaling a major breakthrough in HIV prevention strategies.”
On 3 August 2026, South Africa emerged as the epicenter of a groundbreaking public health initiative: the rollout of lenacapavir (LEN), a twice-yearly HIV prevention injection. With over 31,297 users already enrolled, South Africa accounts for more than half of Africa’s LEN users, underscoring the country’s leadership in HIV prevention.
Background: HIV Burden in South Africa
South Africa has long carried one of the world’s heaviest HIV burdens, with millions living with the virus and thousands of new infections annually. Traditional prevention methods—daily oral pre-exposure prophylaxis (PrEP)—have faced challenges, including adherence issues and stigma. LEN offers a revolutionary alternative: one injection every six months, eliminating the need for daily pills.
Rollout Details
- Start Date: 5 June 2026
- Coverage: 360 government clinics (8% of public clinics) across six provinces
- Uptake: 98.5% of HIV-negative individuals offered LEN chose it over daily pills
- Geographic Concentration: Gauteng and KwaZulu-Natal host two-thirds of users, reflecting both population density and clinic availability.
Public Response
Initial concerns about vaccine hesitancy—stemming from confusion between LEN and COVID-19 vaccines—were quickly dispelled. Health Minister Aaron Motsoaledi emphasized that LEN is not a vaccine but a preventive medicine that blocks HIV entry into cells. The overwhelming uptake demonstrates growing public trust in innovative HIV prevention tools.
Clinical Effectiveness
Clinical trials have shown LEN provides complete protection for young women and near-perfect protection for high-risk groups such as gay and bisexual men and transgender individuals. This broad efficacy makes LEN a cornerstone in reducing HIV transmission across diverse demographics.
Global Context
South Africa is one of ten African countries rolling out LEN, supported by the Global Fund and the U.S. government. Neighboring countries like Zambia and Eswatini report strong adherence, with up to 85% of users returning for their second injection on time. This regional momentum highlights LEN’s potential to reshape HIV prevention across Africa.
Challenges Ahead
- Supply Chain: Ensuring sufficient doses to meet demand remains critical.
- Follow-Up Compliance: Users must return within two weeks of their six-month mark; otherwise, they require additional tablets alongside the injection.
- Equity: Expanding access beyond urban centers to rural clinics is essential to avoid disparities.
Public Health Impact
If scaled effectively, LEN could dramatically reduce new HIV infections in South Africa, aligning with the country’s goal of ending HIV as a public health threat by 2030. The rollout also strengthens South Africa’s reputation as a leader in global health innovation.
Conclusion
The LEN rollout represents a historic milestone in South Africa’s fight against HIV. With strong uptake, proven efficacy, and international support, LEN is poised to transform HIV prevention strategies. The challenge now lies in sustaining momentum, ensuring equitable access, and maintaining adherence to maximize its life-saving potential.
